Domov › Rak mehurja › Tennessee › Nashville
Klinične študije za Rak mehurja v Nashville, TN
31 študij za Rak mehurja išče udeležence na lokacijah v Nashville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Vključevanje udeležencevFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- in še 9
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Vključevanje udeležencevFaza 1
- Urology Associates, P.C., Nashville
DESTINY-PANTUMOUR04
Vključevanje udeležencevOpazovalna študija
- Research Site, Nashville
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Vključevanje udeležencevFaza 3
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831), Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Vključevanje udeležencevFaza 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Vključevanje udeležencevFaza 1
- SCRI, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Vključevanje udeležencevFaza 2
- Urology Associates, PC, Nashville
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Vključevanje udeležencevFaza 2
- Urology Associates PC, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Vključevanje udeležencevFaza 2/3
- Research Site, Nashville
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Vključevanje udeležencevFaza 1
- Sarah Cannon and HCA Research Institute, Nashville
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Vključevanje udeležencevFaza 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Vključevanje udeležencevFaza 1/2
- Urology Associates, P.C., Nashville
- Vanderbilt Univerity Medical Center, Nashville
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Vključevanje udeležencevOpazovalna študija
- Vanderbilt University Medical Center, Nashville
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Vključevanje udeležencevFaza 2/3
- SCRI Oncology Partners, Nashville
- Local Institution - 0084, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Vključevanje udeležencevFaza 2
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Vključevanje udeležencevFaza 3
- Research Site, Nashville
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- US Oncology Research LLC, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Vključevanje udeležencev
- Vanderbilt University Medical Center, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Nashville
Študije za Rak mehurja v drugih mestih
- New York City, NY35 študij
- Houston, TX31 študij
- Dallas, TX27 študij
- Washington, DC26 študij
- Boston, MA26 študij
- Baltimore, MD24 študij
- Los Angeles, CA24 študij
- St. Louis, MO22 študij
- Seattle, WA21 študij
- Chicago, IL21 študij
- Philadelphia, PA21 študij
- Edison, NJ21 študij
Druge študije v Nashville
- Nemalicelični pljučni rak97 študij
- Rak dojke81 študij
- Metastatski rak70 študij
- Kolorektalni rak69 študij
- Rak (vse vrste)65 študij
- Rak jajčnikov49 študij
- Rak prostate43 študij
- Rak pljuč40 študij
- Ploščatocelični karcinom glave in vratu39 študij
- Rak trebušne slinavke39 študij
- Rak endometrija38 študij
- Melanom33 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.